SOURCE: MYOS Corporation

MYOS Corporation

December 04, 2012 09:00 ET

MYOS Announces MYO-X Now Available in GNC; Vitamin Shoppe Soon to Follow

CEDAR KNOLLS, NJ--(Marketwire - Dec 4, 2012) - MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance, announced today that the Company's highly regarded MYO-T12® formulation is now available in the product MYO-X™ at retail powerhouse GNC, through MYOS' premier distributor, MHP. 

MYO-T12 -- the world's first clinically proven myostatin inhibitor -- is being sold under the name MYO-X. The Company has also announced that commencing in January 2013, MYO-X will be available chain-wide at leading retailer, Vitamin Shoppe. The initial shipment of MYO-X to the first Vitamin Shoppe stores will ship the first week in December.

"I am delighted that MYO-X, powered by our MYO-T12 formulation, is now available on the shelves at GNC," said Peter Levy, Chief Operating Officer of MYOS. "As the rollout at GNC progresses, we see sales and awareness growing. Our distribution partner, MHP, is an innovator in fitness and bodybuilding supplements, and has been essential in placing MYO-X in leading retailers like GNC and Vitamin Shoppe. Increasing the retail footprint is central to our growth strategy as we intend to continue to develop and commercialize exciting new products for muscle health." 

MYO-X contains MYOS' breakthrough MYO-T12 formulation, the world's first clinically proven myostatin inhibitor designed to build lean muscle mass and improve strength and endurance. MYO-T12 blocks the activity of myostatin, a regulatory protein which suppresses muscle growth and repair, thereby allowing muscle tissue to recover from injury and respond to exercise more easily. MYOS is actively studying the important role of myostatin modulation in improving the health of muscle tissue for athletes, fitness enthusiasts and those facing the effects of aging and chronic illness. The Company believes MYO-X may represent one of the most effective ways for athletes, bodybuilders and fitness enthusiasts to build lean muscle mass as part of an overall nutrition and exercise program. 

GNC has more than 4,800 retail locations throughout the United States and more than 1,200 Rite-Aid store-within-store locations. The Vitamin Shoppe boasts more than 500 locations in the United States and Puerto Rico. GNC and The Vitamin Shoppe are two of the top vitamin and supplement retailers in the U.S.

About MYOS Corporation

MYOS is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance. MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the rollout of MYO-X in GNC stores, the successful rollout of MYO-X at Vitamin Shoppe, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information

  • Contact:

    Investor Contact
    CEOcast, Inc.
    Bob Woods
    Investor Relations
    Email Contact